 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Celltrion signed a supply contract worth up to 423.6 billion won in the previous quarter
Celltrion announced on the 25th that it has signed a contract with Celltrion Healthcare to supply biosimilars worth about 423.6 billion won.
This contract is the largest quarterly supply contract ever. It is a volume for rapid global supply due to the ever-growing demand for antibody biosimilars in the U.S. and Europe and the growth of new items such as Humira biosimilar Yuflyma and Vegzelma, which have recently been approved for sales in major global markets.
In addition, sales in the second half of the year are expected to increase further if TEVA's consignment production (CMO) supply of migraine medicine is added by the end of this year.
According to pharmaceutical market research firm IQVIA and Celltrion Healthcare (091990), Celltrion's leading autoimmune disease treatment, Remsima, had a market share of 61.7%, Truxima 22.1% and Herzuma 19.2% in the European market in the first quarter of this year.
In the U.S. market, Remsima (U.S. brand name: Inflectra) has a solid market share of 30.2% and Truxima 30.5% as of the second quarter of this year.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
